Buradasınız

Anasayfa » Content

Kell alloimmünizasyonuna bağlı hidrops fetalis: olgu sunumu

Hydrops fetalis due to Kell alloimmunization: a case report

Journal Name:

  • Gülhane Tıp Dergisi

Publication Year:

  • 2011

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
Kell alloimmunization is one of the rare but at the same time most frequent causes of hemolytic disease of fetus and newborn after anti-D alloimmunization. Management of Kell alloimmunization which uniquely demonstrates its effect via the supression of fetal erythropoietic response is somewhat different from alloimmunization occuring due to RhD antibodies. In this case report fetal and neonatal hemolytic disease occuring due to Kell izoimmunization is discussed under the light of literature knowledge regarding a case of hydrops fetalis developing due to sensitization with anti-Kell antibodies and resulting in utero excitus despite intensive follow-up and treatment.
Bookmark/Search this post with
Abstract (Original Language): 
Kell alloimmünizasyonu, fetal ve yenidoğan hemolitik hastalığının anti-D alloimmünizasyonundan sonra en sık izlenen, fakat aynı zamanda nadir rastlanılan nedenlerinden birisidir. Kendine has özelliği ile fetal eritropoetik cevabın baskılanması üzerinden etki eden Kell alloimmünizasyonunun yönetimi RhD antikorları ile oluşan alloimmünizasyondan biraz farklıdır. Bu yazıda anti-Kell antikorları ile sensitizasyon sonucunda oluşan hidrops fetalis ve yoğun tedavi-takibe rağmen in-utero eksitus ile sonuçlanan bir olgu nedeni ile Kell izoimmünizasyonuna bağlı olarak oluşan fetal ve yenidoğan hemolitik hastalığı mevcut literatür bilgisi ışığında tartışılmıştır.
FULL TEXT (PDF): 
PDF icon arastirmax-kell-alloimmunizasyonuna-bagli-hidrops-fetalis-olgu-sunumu.pdf
  • 3
219-222
  • Turkish

REFERENCES

References: 

1. Weinstein L. Irregular antibodies causing hemolytic
disease of the newborn: a continuing problem. Clin
Obstet Gynecol 1982; 25: 321-332.
2. Wenk RE, Goldstein, P, Felix JK. Kell alloimmunization,
hemolytic disease of the newborn, and perinatal
management. Obstet Gynecol 1985; 66: 473-476.
3. Pepperell RJ, Barrie JU, Fliegner JR. Significance of redcell irregular antibodies in the obstetric patient. Med J
Aust 1977; 2: 453-456.
4. Filbey D, Hanson U, Wesstrom G. The prevalence of red
cell antibodies in pregnancy correlated to the outcome
of the newborn: a 12 year study in central Sweden. Acta
Obstet Gynecol Scand 1995; 74: 687-692.
5. Moise KJ Jr. Non-anti-D antibodies in red-cell
alloimmunization. Eur J Obstet Gynecol Reprod Biol
2000; 92: 75-81.
6. Vaughan JI, Manning M, Warwick RM, et al. Inhibition
of erythroid progenitor cells by anti-Kell antibodies
in fetal alloimmune anemia. N Engl J Med 1998; 338:
798-803.
7. Vaughan JI, Warwick R, Letsky E, et al. Erythropoietic
suppression in fetal anemia because of Kell
alloimmunization. Am J Obstet Gynecol 1994; 171:
247-252.
8. Berkowitz RL, Beyth Y, Sadovsky E. Death in utero due
to Kell sensitization without excessive elevation of the
delta OD450 value in amniotic fluid. Obstet Gynecol
1982; 60: 746-749.
9. Bowman JM. Treatment options for the fetus with
alloimmune hemolytic disease. Transfus Med Rev 1990;
4: 191-207.
10. Weiner CP, Widness JA. Decreased fetal erythropoiesis
and hemolysis in Kell hemolytic anemia. Am J Obstet
Gynecol 1996; 174: 547-551.
11. Mari G, Deter RL, Carpenter RL, et al. Noninvasive
diagnosis by Doppler ultrasonography of fetal anemia
due to maternal red-cell alloimmunization. Collaborate
Group for Doppler Assessment of Blood Velocity in
Anemic Fetuses. N Engl J Med 2000; 342: 9-14.
12. van Dongen H, Klumper FJ, Sikkel E, et al. Non-invasive
tests to predict fetal anemia in Kell-alloimmunized
pregnancies. Ultrasound Obstet Gynecol 2005; 25:
341-345.
13. Collinet P, Subtil D, Puech F, et al. Successful
treatment of extremely severe fetal anemia due to
Kell alloimmunization. Obstet Gynecol 2002; 100:
1102-1105.
14. Dhodapkar KM, Blei F. Treatment of hemolytic disease
of the newborn caused by anti-Kell antibody with
recombinant erythropoietin. J Pediatr Hematol Oncol
2001; 23: 69-70.

Thank you for copying data from http://www.arastirmax.com